Alnylam Pharma's market cap is currently ―. The company's EPS TTM is $-3.562; its P/E ratio is -40.79; Alnylam Pharma is scheduled to report earnings on April 25, 2024, and the estimated EPS forecast is $-1.14. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 439.72M	$ 750.53M	$ 305.70M	$ 319.29M	$ 599.42M
Gross Profit	$ 367.74M	$ 671.06M	$ 253.45M	$ 264.42M	$ 548.16M
EBIT	$ -106.35M	$ 181.63M	$ -244.17M	$ -143.41M	$ 88.29M
EBITDA	$ -95.86M	$ 191.84M	$ -233.91M	$ -131.39M	$ 98.87M
Net Income Common Stockholders	$ -194.48M	$ 157.43M	$ -276.02M	$ -174.10M	$ 56.90M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 2.44B	$ 2.41B	$ 2.06B	$ 2.07B	$ 2.19B
Total Assets	$ 3.83B	$ 3.84B	$ 3.40B	$ 3.39B	$ 3.55B
Total Debt	$ 1.31B	$ 1.31B	$ 1.31B	$ 1.32B	$ 1.32B
Net Debt	$ -1.13B	$ -1.10B	$ -743.17M	$ -750.33M	$ -872.16M
Total Liabilities	$ 4.05B	$ 4.00B	$ 3.81B	$ 3.65B	$ 3.55B
Stockholders Equity	$ -220.64M	$ -165.87M	$ -408.13M	$ -259.24M	$ -158.22M
Cash Flow	-
Free Cash Flow	$ -45.10M	$ 342.32M	$ -74.91M	$ -180.37M	$ -153.61M
Operating Cash Flow	$ -29.80M	$ 359.41M	$ -58.99M	$ -166.47M	$ -131.98M
Investing Cash Flow	$ -240.66M	$ -10.76M	$ -8.71M	$ -76.22M	$ -139.91M
Financing Cash Flow	$ 39.23M	$ 33.14M	$ 53.39M	$ 46.37M	$ 63.44M

Currency in USD

Alnylam Pharma Earnings and Revenue History

Income Statement >

Alnylam Pharma Debt to Assets

Balance Sheet >

Alnylam Pharma Cash Flow

Cash Flow >

Alnylam Pharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing